Objective: This study aimed to determine patients’ perspectives regarding the role of dietitians in nutrition management. Methods: This study was conducted at our hospital’s oncology outpatient clinics. It used a questionnaire previously reported in the literature. One hundred sixty-two adult volunteers were included in this study. Patients’ knowledge of nutritional information, preferences for nutrition care, and perspectives on the dietitian’s role were measured. Descriptive statistics were used to describe the continuous variables. The degree of agreement was assessed using a 5-point Likert scale. Results: Nutritional care was a high priority for most volunteers (74.7%). Almost half of the patients expressed a need for dietitians to address their dietary challenges proactively. Most patients (64.2%) first met with a dietitian during ongoing treatment. They emphasized the need for frequent meetings and were willing to be referred to a dietitian earlier in their treatment. Conclusions: Most patients are referred to a dietitian after malnutrition, indicating the need for earlier intervention. Patients strongly desire improved communication among the healthcare team members regarding their nutritional concerns. Proactive nutritional management can reduce the incidence of malnutrition and enhance patient outcomes.

Large B-cell lymphoma (LBCL) patients who fail frontline therapy (R/R-LBCL) experience highly unfavorable outcomes. The development of T-cell redirecting therapies is rapidly evolving this outlook. However, costs and infrastructural challenges limit access to such innovative therapies. This study was conducted to document the shortcomings of management in the absence of regular access to T-cell redirecting therapies in a contemporary patient population and define subgroups with the most urgent need for accessing innovative treatments. The second-line management and outcomes of a large real-world LBCL cohort from Türkiye were retrospectively analyzed with the participation of nine centers from four different geographical regions. Despite the contemporary period (2012-24), there was no regular access to novel agents. The median PFS-2 was 6.9 months. Less than a quarter of patients (24.3%) received transplantation following a response to second-line therapy, the only subgroup who benefited from the standard care (2-year PFS-2: 67.8%). The remaining 295 patients (75.7% of the cohort) had a median survival of 6.1 months and a 2-year PFS-2 of 10.3%. Progression within a year from diagnosis, non-curative intent at second line, and failure of curative second-line therapy were key adverse features for a dismal prognosis, with median survival durations of 8.8, 2, and 7.4 months, respectively. The current therapeutic strategy of intensive chemoimmunotherapy followed by autologous transplantation yields a reasonable chance of survival for only a fifth of patients. The findings emphasize the urgent need for expanding access to T-cell redirecting approaches in R/R LBCL for early progressors, transplant-ineligible cases, those who fail intensive second-line regimens.

Not available Keywords: autoinflammatory vacuolization somatic mutation